S
30.50
0.79 (2.66%)
| Previous Close | 29.71 |
| Open | 30.02 |
| Volume | 2,272,529 |
| Avg. Volume (3M) | 2,552,512 |
| Market Cap | 2,931,881,472 |
| Price / Sales | 13.14 |
| Price / Book | 12.40 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Diluted EPS (TTM) | -2.55 |
| Total Debt/Equity (MRQ) | 20.22% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -229.84 M |
| Levered Free Cash Flow (TTM) | -134.32 M |
| Return on Assets (TTM) | -50.15% |
| Return on Equity (TTM) | -106.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Scholar Rock Holding Corporatio | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 1.25 |
|
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.35% |
| % Held by Institutions | 118.63% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 53.00 (B of A Securities, 73.77%) | Buy |
| Median | 47.00 (54.10%) | |
| Low | 44.00 (Truist Securities, 44.26%) | Buy |
| 44.00 (Barclays, 44.26%) | Buy | |
| 44.00 (HC Wainwright & Co., 44.26%) | Buy | |
| Average | 47.67 (56.30%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 34.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 20 Oct 2025 | 44.00 (44.26%) | Buy | 27.92 |
| B of A Securities | 09 Oct 2025 | 53.00 (73.77%) | Buy | 40.99 |
| Barclays | 24 Sep 2025 | 44.00 (44.26%) | Buy | 33.72 |
| 17 Sep 2025 | 45.00 (47.54%) | Buy | 31.95 | |
| Piper Sandler | 24 Sep 2025 | 51.00 (67.21%) | Buy | 33.72 |
| HC Wainwright & Co. | 23 Sep 2025 | 44.00 (44.26%) | Buy | 33.75 |
| Jefferies | 21 Aug 2025 | 50.00 (63.93%) | Buy | 34.59 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Nov 2025 | Announcement | Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights |
| 12 Nov 2025 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Nov 2025 | Announcement | Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference |
| 23 Oct 2025 | Announcement | Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 |
| 17 Oct 2025 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 23 Sep 2025 | Announcement | FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility |
| 12 Sep 2025 | Announcement | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |